...
首页> 外文期刊>Journal of gastroenterology >Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study
【24h】

Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study

机译:患者报告的结果是盐酸甘露萘氨嘌呤在原发性胆管炎和难治性瘙痒患者中得到改善吗? 营销后,单臂,前瞻性研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BackgroundPatients with primary biliary cholangitis (PBC) frequently suffer from pruritus, which can severely impair their health-related quality of life (HRQOL). Nalfurafine hydrochloride, a selective -opioid receptor agonist, was recently approved in Japan for refractory pruritus in patients with chronic liver diseases, but it still remains unclear whether this treatment improves the patient-reported outcome (PRO) in PBC patients with refractory pruritus. Herein, we conducted a multicenter, post-marketing, single-arm prospective study to investigate the efficacy of nalfurafine in terms of PRO, and the associations of the efficacy with any clinical characteristics.MethodsAfter screening for pruritus in 496 patients with PBC using PBC-40 and the visual analog scale (VAS), we identified 141 patients with moderate to severe pruritus; these were invited to participate in the study. The participants received 2.5g nalfurafine once daily for 12weeks, and pruritus and HRQOL were assessed in week 12 of this treatment. Generic HRQOL, short form 36, blood chemistries, and serum autotaxin levels were also measured at baseline and at week 12.ResultsForty-four patients participated in this study. The mean PBC-40 itch domain scores and VAS declined during the study period, from 8.56 to 7.63 (P=0.041) and from 42.9 to 29.3 (P=0.001) at baseline and at week 12, respectively, indicating a significant effect of nalfurafine. The other domains of PBC-40 and all domains of SF-36 were not significantly altered by this treatment. We failed to find any association between the change in VAS and PBC-40 itch scores and any clinical variable. Serum autotaxin levels were significantly increased during the study period.ConclusionsThis study demonstrated that nalfurafine improved pruritus in patients with PBC, independent of their clinical characteristics, but had a limited effect on the PRO.
机译:具有原发性胆管炎(PBC)的背景患者经常遭受瘙痒症,这可能会严重损害其与健康相关的生命质量(HRQOL)。最近选择性 - 己酰亚胺受体激动剂盐酸纳嘌呤素最近在日本批准慢性肝病患者的难治性瘙痒,但仍然尚不清楚这种治疗是否改善了PBC患者难治性瘙痒患者的患者报告的结果(Pro)。在此,我们进行了多中心,营销后的单臂前瞻性研究,以研究NALFURAFINE在PRO方面的疗效,以及疗效与任何临床特征的疗效。使用PBC的496名PBC患者的瘙痒症筛选出来40和视觉模拟量表(VAS),我们确定了141例中度至重度瘙痒的患者;这些被邀请参加该研究。参与者每天收到2.5g Nalfurafine,每天服用12周,并且在该处理的第12周评估瘙痒和HRQOL。在基线和第12周,还测量了通用HRQOL,短型36,血液化学和血清自陶蛋白水平。悲伤 - 四名患者参加了这项研究。在研究期间,平均PBC-40痒结构域分数和VAS下降,从8.56至7.63(p = 0.041),分别在基线和第12周的42.9至29.3(p = 0.001),表明NALFURAFINE的显着效果。 PBC-40的其他结构域和SF-36的所有结构域未通过该处理显着改变。我们未能找到VAS和PBC-40 ITCH分数和任何临床变量之间的任何关联。在研究期间血清自坦水平显着增加。结论性研究表明,纳尔芬丁脒在PBC患者中改善瘙痒,与其临床特征无关,但对PRO有有限的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号